Talphera Inc. (TLPH)
0.62
-0.01 (-0.97%)
At close: Feb 20, 2025, 3:52 PM
0.61
-1.15%
After-hours: Feb 20, 2025, 03:52 PM EST
undefined% (undefined)
| Bid | 0.6 |
| Market Cap | 10.54M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.7 |
| PE Ratio (ttm) | -0.88 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.64 |
| Volume | 59,677 |
| Avg. Volume (20D) | 97,416 |
| Open | 0.62 |
| Previous Close | 0.63 |
| Day's Range | 0.61 - 0.64 |
| 52-Week Range | 0.50 - 1.50 |
| Beta | undefined |
About TLPH
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditi...
Sector Healthcare
IPO Date Feb 11, 2011
Employees 15
Stock Exchange NASDAQ
Ticker Symbol TLPH
Website https://talphera.com
Analyst Forecast
According to 2 analyst ratings, the average rating for TLPH stock is "Buy." The 12-month stock price forecast is $4.5, which is an increase of 626.86% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago
-25.61%
Talphera shares are trading lower. The company rep...
Unlock content with
Pro Subscription
6 months ago
-5.49%
Talphera shares are trading higher after the company reported better-than-expected Q2 EPS results.
